SCHEMBL2007034

SCHEMBL2007034

Cc1nn(-c2ccc(OCc3ccccc3)c(F)c2)c2cccc(OCc3ccccc3)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
MAPK1 P28482 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
STAT3 P40763 2/20 0.41
HTT P42858 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MRGPRX4 Q96LA9 2/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
CYP19A1 P11511 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
S1PR5 Q9H228 1/20 0.39
KDM1A O60341 2/20 0.39
BRD4 O60885 1/20 0.39
PTGER1 P34995 1/20 0.39
EDNRA P25101 1/20 0.37
ATP4A P20648 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2006258 0.78 NR3C1 (0.41) MAPTMAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL14085312 0.78 CYP11B1 (0.42) MAPTMAPK1TDP1L3MBTL1MRGPRX4
SCHEMBL8531760 0.75 LMNA (0.43) MAPTMAPK1TDP1L3MBTL1STAT3
SCHEMBL2003613 0.73 MAPK14 (0.44) MRGPRX4S1PR5PTGER1
SCHEMBL2003916 0.73 S1PR5 (0.40) MAPTSMN1; SMN2MRGPRX4POLBCYP11B1
SCHEMBL1014598 0.73 ROCK1 (0.53) MAPTMAPK1TDP1L3MBTL1MRGPRX4
SCHEMBL5069111 0.73 MRGPRX4 (0.44) STAT3HTTSMN1; SMN2MRGPRX4CYP2C9
SCHEMBL29254805 0.73 MRGPRX4 (0.49) MAPTMAPK1TDP1L3MBTL1MRGPRX4
SCHEMBL14085379 0.73 MAPK14 (0.41) MAPTSMN1; SMN2MRGPRX4LMNAPOLB
SCHEMBL27503015 0.72 MAPT (0.41) MAPTMAPK1TDP1L3MBTL1MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
EP-2118068-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS Glaxo Group Limited (GB) 2009-11-18 EP disclosed
WO-2008107455-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-09-12 WO disclosed
WO-2008107455-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GPER1, ESR2, ESRRB MAPT 2061/4885MAPK1 4030/4885TDP1 3952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.